Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs.

M E Ganapathy, V Ganapathy
{"title":"Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs.","authors":"M E Ganapathy,&nbsp;V Ganapathy","doi":"10.2174/156800805774912953","DOIUrl":null,"url":null,"abstract":"<p><p>ATB(0,+) is a unique amino acid transporter because of its broad substrate specificity and concentrative ability. This transporter recognizes neutral as well as cationic amino acids. It is energized by Na(+) and Cl(-) gradients and membrane potential. Many of the amino acids and amino acid derivatives that are substrates for ATB(0,+) serve as therapeutic agents (e.g., D-serine, carnitine, and nitric oxide synthase inhibitors). Recent studies have shown that the potential of ATB(0,+) as a drug delivery system may be greater than previously envisaged. ATB(0,+) can transport antiviral drugs such as acyclovir and ganciclovir when they are covalently coupled to the side chain of anionic amino acids. Chemical modification of the carboxyl groups in the side chain of aspartate and glutamate with drugs converts these anionic amino acids into neutral amino acid derivatives. Therefore, the modified drugs are recognized by ATB(0,+). Interestingly, even when acyclovir and ganciclovir are coupled as esters with alpha-carboxyl group of neutral amino acids, the modified drugs are transported via ATB(0,+). Similarly, the hydroxyl group in the side chains of serine and threonine can also be used to covalently couple drugs for delivery into cells via ATB(0,+). This increases the potential for designing a wide variety of amino acid-based prodrugs that can utilize ATB(0,+) as drug delivery system. Furthermore, the transporter is expressed in the colon, lung, and eye, the tissues easily amenable for drug delivery. These findings argue strongly in support of ATB(0,+) as a potential delivery system for a wide variety of drugs and prodrugs.</p>","PeriodicalId":84524,"journal":{"name":"Current drug targets. Immune, endocrine and metabolic disorders","volume":"5 4","pages":"357-64"},"PeriodicalIF":0.0000,"publicationDate":"2005-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/156800805774912953","citationCount":"47","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug targets. Immune, endocrine and metabolic disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/156800805774912953","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 47

Abstract

ATB(0,+) is a unique amino acid transporter because of its broad substrate specificity and concentrative ability. This transporter recognizes neutral as well as cationic amino acids. It is energized by Na(+) and Cl(-) gradients and membrane potential. Many of the amino acids and amino acid derivatives that are substrates for ATB(0,+) serve as therapeutic agents (e.g., D-serine, carnitine, and nitric oxide synthase inhibitors). Recent studies have shown that the potential of ATB(0,+) as a drug delivery system may be greater than previously envisaged. ATB(0,+) can transport antiviral drugs such as acyclovir and ganciclovir when they are covalently coupled to the side chain of anionic amino acids. Chemical modification of the carboxyl groups in the side chain of aspartate and glutamate with drugs converts these anionic amino acids into neutral amino acid derivatives. Therefore, the modified drugs are recognized by ATB(0,+). Interestingly, even when acyclovir and ganciclovir are coupled as esters with alpha-carboxyl group of neutral amino acids, the modified drugs are transported via ATB(0,+). Similarly, the hydroxyl group in the side chains of serine and threonine can also be used to covalently couple drugs for delivery into cells via ATB(0,+). This increases the potential for designing a wide variety of amino acid-based prodrugs that can utilize ATB(0,+) as drug delivery system. Furthermore, the transporter is expressed in the colon, lung, and eye, the tissues easily amenable for drug delivery. These findings argue strongly in support of ATB(0,+) as a potential delivery system for a wide variety of drugs and prodrugs.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
氨基酸转运体ATB0,+作为药物和前药的递送系统。
ATB(0,+)是一种独特的氨基酸转运蛋白,具有广泛的底物特异性和浓缩能力。这种转运体既能识别中性氨基酸,也能识别阳离子氨基酸。它是由Na(+)和Cl(-)梯度和膜电位激发的。许多氨基酸和氨基酸衍生物是ATB(0,+)的底物,可作为治疗剂(例如,d -丝氨酸,肉碱和一氧化氮合酶抑制剂)。最近的研究表明,ATB(0,+)作为药物递送系统的潜力可能比以前设想的要大。当ATB(0,+)与阴离子氨基酸侧链共价偶联时,可以转运诸如阿昔洛韦和更昔洛韦等抗病毒药物。用药物对天冬氨酸和谷氨酸侧链上的羧基进行化学修饰,将这些阴离子氨基酸转化为中性氨基酸衍生物。因此,修饰后的药物被ATB(0,+)识别。有趣的是,即使当阿昔洛韦和更昔洛韦作为酯与中性氨基酸的-羧基偶联时,修饰后的药物也通过ATB(0,+)运输。类似地,丝氨酸和苏氨酸侧链上的羟基也可以用来共价偶联药物,通过ATB(0,+)将药物递送到细胞中。这增加了设计多种基于氨基酸的前药的潜力,这些前药可以利用ATB(0,+)作为给药系统。此外,转运蛋白在结肠、肺和眼睛中表达,这些组织容易适应药物输送。这些发现有力地支持ATB(0,+)作为多种药物和前药的潜在递送系统。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Signal transducer and activator of transcription 5 (STAT5), a crucial regulator of immune and cancer cells. Boosting interleukin-10 production: therapeutic effects and mechanisms. Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs. Augmenting T helper cell immunity in cancer. Management of liver disease in thalassemia: main drug targets for a correct therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1